Clinical Trial Update: Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET [Phase 2]

View source ↗

Summary

Phase 2 trial of MGCD265 in non-small cell lung cancer with activating MET alterations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MGCD265 (MGCD265)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-09-10